Eli Lilly presents positive data from tirzepatide sub-studies
Substudies connected to Eli Lilly's Supass 3 phase III trial have generated favorable results for the candidate when compared to Novo Nordisk's long-acting insulin Tresiba
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
US-based pharmaceutical company Eli Lilly has presented several positive results for the drug candidate tirzepatide, which is a combination of the two hormones known respectively as GLIP-1 and GIP, at the annual meeting of the European Association for the Study of Diabetes (EASD). The company reports this in two seperate press releases on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
